These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

268 related items for PubMed ID: 29205458

  • 1. Multidisciplinary management of refractory insulinomas.
    Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ.
    Clin Endocrinol (Oxf); 2018 May; 88(5):615-624. PubMed ID: 29205458
    [Abstract] [Full Text] [Related]

  • 2. New therapeutic options for metastatic malignant insulinomas.
    de Herder WW, van Schaik E, Kwekkeboom D, Feelders RA.
    Clin Endocrinol (Oxf); 2011 Sep; 75(3):277-84. PubMed ID: 21649688
    [Abstract] [Full Text] [Related]

  • 3. Emerging therapies for advanced insulinomas and glucagonomas.
    Alexandraki KI, Kaltsas GA, Grozinsky-Glasberg S.
    Endocr Relat Cancer; 2023 Sep 01; 30(9):. PubMed ID: 37343152
    [Abstract] [Full Text] [Related]

  • 4. Approach to the Patient: Insulinoma.
    Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW.
    J Clin Endocrinol Metab; 2024 Mar 15; 109(4):1109-1118. PubMed ID: 37925662
    [Abstract] [Full Text] [Related]

  • 5. Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: case report and review of the literature.
    Scharf M, Mueller D, Koenig U, Pfestroff A, Nimphius W, Figiel J, Rinke A, Koenig A, Gress T.
    Pancreatology; 2014 Mar 15; 14(6):542-5. PubMed ID: 25459566
    [Abstract] [Full Text] [Related]

  • 6. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK, Khan MS, Toumpanakis C, Caplin ME.
    Minerva Gastroenterol Dietol; 2009 Dec 15; 55(4):425-43. PubMed ID: 19942827
    [Abstract] [Full Text] [Related]

  • 7. Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.
    Oziel-Taieb S, Maniry-Quellier J, Chanez B, Poizat F, Ewald J, Niccoli P.
    Front Endocrinol (Lausanne); 2022 Dec 15; 13():860614. PubMed ID: 35518928
    [Abstract] [Full Text] [Related]

  • 8. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies.
    Ito T, Lee L, Jensen RT.
    Expert Opin Pharmacother; 2016 Nov 15; 17(16):2191-2205. PubMed ID: 27635672
    [Abstract] [Full Text] [Related]

  • 9. Diagnosis and management of neuroendocrine tumours.
    Cuthbertson DJ, Shankland R, Srirajaskanthan R.
    Clin Med (Lond); 2023 Mar 15; 23(2):119-124. PubMed ID: 36958842
    [Abstract] [Full Text] [Related]

  • 10. Update in the Therapy of Advanced Neuroendocrine Tumors.
    Uri I, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S.
    Curr Treat Options Oncol; 2017 Nov 16; 18(12):72. PubMed ID: 29143892
    [Abstract] [Full Text] [Related]

  • 11. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
    Fazio N, Cinieri S, Lorizzo K, Squadroni M, Orlando L, Spada F, Maiello E, Bodei L, Paganelli G, Delle Fave G, de Braud F.
    Cancer Treat Rev; 2010 Nov 16; 36 Suppl 3():S87-94. PubMed ID: 21129617
    [Abstract] [Full Text] [Related]

  • 12. Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.
    Dawod M, Gordoa TA, Cives M, De Mestier L, Crona J, Spada F, Oberg K, Pavel M, Lamarca A.
    Curr Treat Options Oncol; 2021 Jun 29; 22(8):73. PubMed ID: 34185197
    [Abstract] [Full Text] [Related]

  • 13. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma.
    Ong GS, Henley DE, Hurley D, Turner JH, Claringbold PG, Fegan PG.
    Eur J Endocrinol; 2010 May 29; 162(5):1001-8. PubMed ID: 20164213
    [Abstract] [Full Text] [Related]

  • 14. [Drug therapy for neuroendocrine tumours].
    Tóth M.
    Orv Hetil; 2013 Sep 29; 154(39):1556-64. PubMed ID: 24058101
    [Abstract] [Full Text] [Related]

  • 15. Percutaneous Microwave Ablation of an Insulinoma in a Patient with Refractory Symptomatic Hypoglycemia.
    Chen OT, Dojki FK, Weber SM, Hinshaw JL.
    J Gastrointest Surg; 2015 Jul 29; 19(7):1378-81. PubMed ID: 25941027
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
    Faggiano A, Modica R, Severino R, Camera L, Fonti R, Del Prete M, Chiofalo MG, Aria M, Ferolla P, Vitale G, Pezzullo L, Colao A.
    Endocrine; 2018 Oct 29; 62(1):46-56. PubMed ID: 29572709
    [Abstract] [Full Text] [Related]

  • 18. Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors.
    Hauser H, Gerson DS, Reidy-Lagunes D, Raj N.
    Curr Treat Options Oncol; 2019 Nov 27; 20(12):87. PubMed ID: 31776785
    [Abstract] [Full Text] [Related]

  • 19. Pancreatic neuroendocrine tumours.
    Alexakis N, Neoptolemos JP.
    Best Pract Res Clin Gastroenterol; 2008 Nov 27; 22(1):183-205. PubMed ID: 18206821
    [Abstract] [Full Text] [Related]

  • 20. Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy.
    Chan JA, Kulke MH.
    Surg Oncol Clin N Am; 2016 Apr 27; 25(2):423-37. PubMed ID: 27013373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.